» Articles » PMID: 11836664

The Pathogenesis of Mesothelioma

Overview
Journal Semin Oncol
Specialty Oncology
Date 2002 Feb 12
PMID 11836664
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

About 80% of malignant mesotheliomas (MM) in the Western World develop in individuals with higher than background exposure to asbestos. Only a fraction of those exposed to asbestos develop mesothelioma, indicating that additional factors play a role. Simian virus 40 (SV40), a DNA tumor virus that preferentially causes mesothelioma in hamsters, has been detected in several human mesotheliomas. The expression of the SV40 large tumor antigen in mesothelioma cells, and not in nearby stromal cells, and the capacity of antisense T-antigen treatment to arrest mesothelioma cell growth in vitro suggest that SV40 contributes to tumor development. The capacity of T-antigen to bind and inhibit cellular p53 and retinoblastoma (Rb)-family proteins in mesothelioma, together with the very high susceptibility of human mesothelial cells to SV40-mediated transformation in vitro, supports a causative role of SV40 in the pathogenesis of mesothelioma. Asbestos appears to increase SV40-mediated transformation of human mesothelial cells in vitro, suggesting that asbestos and SV40 may be cocarcinogens. p53 mutations are rarely found in mesothelioma; p16, p14ARF, and NF2 mutations/losses are frequent. Recent studies revealed the existence of a genetic factor that predisposes affected individuals to mesothelioma in the villages of Karain and Tuzkoy, in Anatolia, Turkey. Erionite, a type of zeolite, may be a cofactor in these same villages, where 50% of deaths are caused by mesothelioma. Mesothelioma appears to have a complex etiology in which environmental carcinogens (asbestos and erionite), ionizing radiation, viruses, and genetic factors act alone or in concert to cause malignancy.

Citing Articles

Mesothelioma Cases in the World Trade Center Survivors.

Yilmaz M, Rashidfarokhi M, Pollard K, Durmus N, Keserci S, Sterman D Ann Case Rep. 2024; 9(2).

PMID: 39568634 PMC: 11578103. DOI: 10.29011/2574-7754.101709.


The aftermath of asbestos prohibition in industry and its association with malignant mesothelioma in the south of Iran: An enduring predicament yet to be resolved.

Rezvani A, Shahriarirad R, Jahanshahi S, Fouladi D, Tavallali M, Ziaian B Health Sci Rep. 2024; 7(10):e70117.

PMID: 39377019 PMC: 11456676. DOI: 10.1002/hsr2.70117.


Deciphering the role of claudins in lung cancer.

Arabi T, Alkattan W, Osman N, Sabbah B, Ashraf N, Ouban A Front Oncol. 2024; 14:1435535.

PMID: 39364319 PMC: 11446878. DOI: 10.3389/fonc.2024.1435535.


Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project.

Ruschoff J, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L Mod Pathol. 2022; 35(12):1888-1899.

PMID: 36115922 PMC: 9708564. DOI: 10.1038/s41379-022-01145-0.


Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors.

Nash A, Aghlara-Fotovat S, Castillio B, Hernandez A, Pugazenthi A, Lee H Clin Cancer Res. 2022; 28(23):5121-5135.

PMID: 35993913 PMC: 9713361. DOI: 10.1158/1078-0432.CCR-22-1493.